290 related articles for article (PubMed ID: 30261996)
21. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
[No Abstract] [Full Text] [Related]
22. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
23. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
25. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
[TBL] [Abstract][Full Text] [Related]
26. Beclometasone for chronic obstructive pulmonary disease.
De Coster DA; Jones M; Thakrar N
Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
[TBL] [Abstract][Full Text] [Related]
27. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal.
Barnes PJ; Nicolini G; Bizzi A; Spinola M; Singh D
Allergy Asthma Proc; 2012; 33(2):140-4. PubMed ID: 22525390
[TBL] [Abstract][Full Text] [Related]
28. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P; Matera MG; Facciolo F; Page C; Cazzola M; Calzetta L
Br J Pharmacol; 2020 Mar; 177(5):1150-1163. PubMed ID: 31660611
[TBL] [Abstract][Full Text] [Related]
29. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
30. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
32. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
33. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
34. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults.
Ni CM; Greenstone IR; Ducharme FM
Cochrane Database Syst Rev; 2005 Apr; (2):CD005307. PubMed ID: 15846751
[TBL] [Abstract][Full Text] [Related]
35. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology.
Acerbi D; Brambilla G; Kottakis I
Pulm Pharmacol Ther; 2007; 20(3):290-303. PubMed ID: 16890465
[TBL] [Abstract][Full Text] [Related]
36. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.
Scichilone N; Benfante A; Morandi L; Bellini F; Papi A
Patient Relat Outcome Meas; 2014; 5():153-62. PubMed ID: 25473323
[TBL] [Abstract][Full Text] [Related]
37. TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
Marth K; Renner A; Pohl W
Respir Med; 2021 Jun; 182():106398. PubMed ID: 33901786
[TBL] [Abstract][Full Text] [Related]
38. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
[TBL] [Abstract][Full Text] [Related]
40. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
